GW Pharmaceuticals initiated at Oppenheimer

GW Pharmaceuticals initiated with a Perform at Oppenheimer. Oppenheimer analyst Esther Rajavelu started GW Pharmaceuticals with a Perform rating and $142 price target. With Epidiolex, a first-in-class phytocannabidiol medication for the treatment of certain types of seizures, the company is well positioned for both revenue growth and pipeline expansion, Rajavelu tells investors in a research note. However, the analyst believes GW’s positive drivers are fairly reflected in the stock at current levels.
https://thefly.com/landingPageNews.php?id=2835625